Announcement on Completing the Issuance of H Shares
Filed with SSE · · 2 pages · Chinese
Earlier from RemeGen
- RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
- Notice on Convening the 2024 Annual General Meeting, the 1st A-share General Meeting of 2025, and the 1st H-Share General Meeting of 2025
- Announcement on Reply to Letter of Regulatory Inquiry from Shanghai Stock Exchange
- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Shandong Jurisdiction
- Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
Later from RemeGen
- 2025 ASCO |Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
- Indicative Announcement on Obtaining Term Compensation for Core Drug Patent
- RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
- Announcement on Resolutions of the 2024 Annual General Meeting, the 1st A-Share Shareholders' Meeting and the 1st H-Share Shareholders' Meeting in 2025
- RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
Follow RemeGen into a list and get an email when it puts out news.
Follow RemeGen